Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Pacific Biosciences of California Inc
PACB
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.27
0.02
0.89%
Ult. Agg.: Oct 27, 9:16 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 8 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Pacific Biosciences Financials
Pacific Biosciences (PACB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.
Benzinga Newsdesk
PRO
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of $(0.13) per share
Benzinga Newsdesk
PRO
Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.
Benzinga Newsdesk
PRO
Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of $(0.15) per share from
Benzinga Newsdesk
Insights into Pacific Biosciences Q4 Earnings
Benzinga Insights
PRO
Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
